a Syreon Research Institute , Budapest , Hungary.
b Janssen Research & Development , High Wycombe , UK.
Expert Rev Hematol. 2019 May;12(5):295-309. doi: 10.1080/17474086.2019.1602036. Epub 2019 Apr 14.
Chronic graft-versus-host disease (GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to provide a systematic overview of evidence on the health-related quality of life (HRQoL) and functional capacity of HSCT patients with National Institutes of Health (NIH)-defined chronic GVHD. Areas covered: English-language articles published between 2007 and 2017 were searched using PubMed. Studies that used the 2005 or 2015 NIH consensus criteria for the diagnosis and staging of chronic GVHD and had a cohort size of at least 100 patients were included. Expert opinion: Disease severity and organ involvement were the most important predictors of HRQoL and functionality in chronic GVHD patients. Further, identified predictors of HRQoL were nutrition status and functional capacity, while functional status was also associated with disease symptoms, nutrition status, age, and survival. Data regarding the effect of symptom bother on HRQoL were limited. Our findings confirm that the management of chronic GVHD should focus on improving not only clinical outcomes but also on HRQoL and functional capacity. Therefore, to evaluate new treatment options it is recommended to include patient relevant endpoints into prospective studies. This study also highlights the importance of nonpharmacological aspects in the management of chronic GVHD.
慢性移植物抗宿主病(GVHD)是异基因造血干细胞移植(HSCT)的严重并发症。本研究旨在对 NIH 定义的慢性 GVHD 患者的健康相关生活质量(HRQoL)和功能能力进行系统综述。涵盖领域:使用 PubMed 搜索了 2007 年至 2017 年发表的英文文章。纳入标准为:使用 2005 年或 2015 年 NIH 慢性 GVHD 诊断和分期共识标准,且队列大小至少为 100 例的研究。专家意见:疾病严重程度和器官受累是慢性 GVHD 患者 HRQoL 和功能的最重要预测因素。此外,HRQoL 的预测因素包括营养状况和功能能力,而功能状态也与疾病症状、营养状况、年龄和生存有关。关于症状困扰对 HRQoL 影响的数据有限。我们的研究结果证实,慢性 GVHD 的治疗管理应不仅关注临床结果,还要关注 HRQoL 和功能能力。因此,建议将患者相关终点纳入前瞻性研究,以评估新的治疗选择。本研究还强调了在慢性 GVHD 管理中非药物方面的重要性。